✦ LIBER ✦

The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option?

✍ Scribed by Th. Delaunoit; M. Ducreux; V. Boige; C. Dromain; J.-C. Sabourin; P. Duvillard; M. Schlumberger; T. de Baere; P. Rougier; P. Ruffie; D. Elias; P. Lasser; E. Baudin

Book ID: 116428005
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 165 KB
Volume: 40
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2003.09.035

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FDA Approval Summary: Sunitinib for the

FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors

✍ Blumenthal, G. M.; Cortazar, P.; Zhang, J. J.; Tang, S.; Sridhara, R.; Murgo, A. 📂 Article 📅 2012 🏛 Alphamed Press 🌐 English ⚖ 137 KB